Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Glycyl-L-Histidyl-L-Lysine
GHK is the parent tripeptide Gly-His-Lys, originally isolated from human plasma by Loren Pickart (1973) as an activity that caused aged hepatocytes to synthesize proteins like younger tissue. It is DISTINCT from GHK-Cu, the 1:1 copper(II) complex tracked as a separate entry — but GHK binds copper readily in vivo, so in physiological environments the bare peptide rapidly associates with available Cu(II). Not FDA-approved for any indication; used in cosmetic and research contexts only.
GHK is a high-affinity ligand for copper(II), forming the GHK-Cu complex that mediates most of its documented biology. Via the copper-bound form, GHK is proposed to modulate expression of a large number of human genes (microarray and Broad Institute Connectivity Map analyses from Pickart's group), including pathways related to extracellular matrix remodeling, antioxidant response element induction, angiogenesis, and DNA repair. Reported in vitro and preclinical effects include stimulation of fibroblast collagen and glycosaminoglycan synthesis and acceleration of wound healing. The bare (non-copper) peptide is typically weaker than GHK-Cu in these assays and is generally assumed to acquire copper in serum-containing environments.
The overwhelming majority of GHK research uses the GHK-Cu complex; direct studies of copper-free GHK are limited. Pickart (J Biomater Sci Polym Ed, 2008, PMID 18644225) reviewed GHK's role in tissue remodeling and wound healing. Pickart et al. (Oxid Med Cell Longev, 2012, PMID 22666519) reviewed GHK-Cu in oxidative stress and cognitive aging. Pickart, Vasquez-Soltero & Margolina (BioMed Res Int, 2014, PMID 25302294; 'GHK and DNA: Resetting the Human Genome to Health') summarized microarray data indicating GHK modulates expression of thousands of human genes. No human clinical trials exist for injected bare GHK; cosmetic formulations typically use topical GHK or GHK-Cu at ~50–200 ppm.
Typical Dose
50–200 ppm topical (~0.005–0.02%)
Frequency
Daily
Route
Topical
Notes
Primarily a cosmetic / research peptide. No validated human injectable dose; grey-market SubQ protocols sometimes cite 0.5–1 mg but are not supported by clinical data. In aqueous formulation GHK will chelate available copper and convert to GHK-Cu. Store lyophilized at -20°C protected from light; reconstituted solutions oxidize readily.
This platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.